Skip to main content
Fig. 1 | Cell Communication and Signaling

Fig. 1

From: Inhibition of CRM1 activity sensitizes endometrial and ovarian cell lines to TRAIL-induced cell death

Fig. 1

Leptomycin B combination therapy significantly reduces cell viability in a tumor specific manner. a Studied cell lines were treated with increasing concentration of cisplatin (0-80 μM) and TRAIL (0-200 ng/mL) in presence or absence of leptomycin B (20 nM) for 24 h. The MTT was then used to determine the resultant changes in cell viability. Results shown are representative of three independent experiments. b Comparison between the combined therapy results of every cell line for both chemotherapeutic agents. c Kaplan Meier plot showing the significantly increased survival rate found in ovarian cancer patients presenting low level of CRM1 expression; obtained from dataset GSE9891/235927_at d Box plot illustrating the significantly increased CRM1 expression in the context of carboplatin-resistant patient ovarian tumor samples; obtained from dataset GDS1381/37729_at. Except for c, in which n number is indicated specifically, all data are means ± SEM of three independent experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001

Back to article page
\